Long-term clinical observation of patients with acute and chronic complete spinal cord injury after transplantation of NeuroRegen scaffold

Tang, Fengwu; Tang, Jiaguang; Zhao, Yannan; Zhang, Jiaojiao; Xiao, Zhifeng; Chen, Bing; Han, Guang; Yin, Na; Jiang, Xianfeng; Zhao, Changyu; Cheng, Shixiang; Wang, Ziqiang; Chen, Yumei; Chen, Qiaoling; Song, Keran; Zhang, Zhiwei; Niu, Junjie; Wang, Lingjun; Shi, Qin; Chen, Liang; Yang, Huilin; Hou, Shuxun; Zhang, Sai

doi:10.1007/s11427-021-1985-5

Cited by 38 publications

(40 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The NeuroRegen scaffold was also reported to be transplanted into 51 chronic complete SCI patients, resulting in 16 patients achieving expansion of their sensation level and 30 patients experiencing enhanced reflexive defecation sensation or increased skin sweating below the injury site. Nearly half of the patients with chronic cervical SCI developed enhanced finger activity (Tang et al, 2021). The study also revealed that increased finger activity, enhanced trunk stability, defecation sensation, and recovery of autonomic neural function were observed in some patients following transplantation of the NeuroRegen scaffold combined with human MSCs (Zhao et al, 2017).…”

Section: Tissue Engineering Approaches For Chronic Spinal Cord Injurymentioning

confidence: 80%

Current Concepts of Neural Stem/Progenitor Cell Therapy for Chronic Spinal Cord Injury

Suzuki

Imajo

Funaba

et al. 2022

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Chronic spinal cord injury (SCI) is a devastating condition that results in major neurological deficits and social burden. It continues to be managed symptomatically, and no real therapeutic strategies have been devised for its treatment. Neural stem/neural progenitor cells (NSCs/NPCs) being used for the treatment of chronic SCI in experimental SCI models can not only replace the lost cells and remyelinate axons in the injury site but also support their growth and provide neuroprotective factors. Currently, several clinical studies using NSCs/NPCs are underway worldwide. NSCs/NPCs also have the potential to differentiate into all three neuroglial lineages to regenerate neural circuits, demyelinate denuded axons, and provide trophic support to endogenous cells. This article explains the challenging pathophysiology of chronic SCI and discusses key NSC/NPC-based techniques having the greatest potential for translation over the next decade.

show abstract

Section: Tissue Engineering Approaches For Chronic Spinal Cord Injurymentioning

confidence: 80%

Current Concepts of Neural Stem/Progenitor Cell Therapy for Chronic Spinal Cord Injury

Suzuki

Imajo

Funaba

et al. 2022

Front. Cell. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Therefore, for a clearer comparison of the efficacy and safety of transplanted cells from different sources, it remains necessary to explore the above-mentioned still unclear conclusions. Recently, the study of cell transplantation combined with scaffold in the treatment of SCI is gradually carried out (Xiao et al, 2018 ; Chen et al, 2020 ; Deng et al, 2020 ; Kim et al, 2021 ; Tang et al, 2021 ). An observational study (Tang et al, 2021 ) with a follow-up of 2–5 years found varying degrees of recovery of sensory levels and increased defecation reflexes after cell transplantation combined with scaffold therapy in patients with acute or chronic SCI.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, the study of cell transplantation combined with scaffold in the treatment of SCI is gradually carried out (Xiao et al, 2018 ; Chen et al, 2020 ; Deng et al, 2020 ; Kim et al, 2021 ; Tang et al, 2021 ). An observational study (Tang et al, 2021 ) with a follow-up of 2–5 years found varying degrees of recovery of sensory levels and increased defecation reflexes after cell transplantation combined with scaffold therapy in patients with acute or chronic SCI. This allows patients and physicians afflicted with spinal cord injury to have more expectations.…”

Section: Discussionmentioning

confidence: 99%

Comparing the Efficacy and Safety of Cell Transplantation for Spinal Cord Injury: A Systematic Review and Bayesian Network Meta-Analysis

Liang

Lin

et al. 2022

Front. Cell. Neurosci.

View full text Add to dashboard Cite

ObjectiveTo compare the safety and effectiveness of transplanted cells from different sources for spinal cord injury (SCI).DesignA systematic review and Bayesian network meta-analysis.Data SourcesMedline, Embase, and the Cochrane Central Register of Controlled Trials.Study SelectionWe included randomized controlled trials, case–control studies, and case series related to cell transplantation for SCI patients, that included at least 1 of the following outcome measures: American Spinal Cord Injury Association (ASIA) Impairment Scale (AIS grade), ASIA motor score, ASIA sensory score, the Functional Independence Measure score (FIM), International Association of Neurorestoratology Spinal Cord Injury Functional Rating Scale (IANR-SCIFRS), or adverse events. Follow-up data were analyzed at 6 and 12 months.ResultsForty-four eligible trials, involving 1,266 patients, investigated 6 treatments: olfactory ensheathing cells (OECs), neural stem cells/ neural progenitor cells (NSCs), mesenchymal stem cells (MSCs), Schwann cells, macrophages, and combinations of cells (MSCs plus Schwann cells). Macrophages improved the AIS grade at 12 months (mean 0.42, 95% credible interval: 0–0.91, low certainty) and FIM score at 12 months (42.83, 36.33–49.18, very low certainty). MSCs improved the AIS grade at 6 months (0.42, 0.15–0.73, moderate certainty), the motor score at 6 months (4.43, 0.91–7.78, moderate certainty), light touch at 6 (10.01, 5.81–13.88, moderate certainty) and 12 months (11.48, 6.31–16.64, moderate certainty), pinprick score at 6 (14.54, 9.76–19.46, moderate certainty) and 12 months (12.48, 7.09–18.12, moderate certainty), and the IANR-SCIFRS at 6 (3.96, 0.62–6.97, moderate certainty) and 12 months (5.54, 2.45–8.42, moderate certainty). OECs improved the FIM score at 6 months (9.35, 1.71–17.00, moderate certainty). No intervention improved the motor score significantly at 12 months. The certainty of other interventions was low or very low. Overall, the number of adverse events associated with transplanted cells was low.ConclusionsPatients with SCI who receive transplantation of macrophages, MSCs, NSCs, or OECs may have improved disease prognosis. MSCs are the primary recommendations. Further exploration of the mechanism of cell transplantation in the treatment of SCI, transplantation time window, transplantation methods, and monitoring of the number of transplanted cells and cell survival is needed.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/#recordDetails, identifier: CRD 42021282043.

show abstract

“…Scaffold-based strategies to construct regenerative microenvironment may represent a feasible therapeutic approach for patients with SCI ( Zhao et al, 2017 ). Combined transplantation of NeuroRegen scaffolds and SCs has been proved to promote neurological regeneration in clinical studies of both acute and chronic complete SCI ( Tang et al, 2021 ). Deng and Zhao et al found that transplantation of human umbilical cord-mesenchymal stem cells (hUCB-MSCs) or patients’ own bone marrow mononuclear cells on collagen scaffolds can contribute to neurological recovery after acute or chronic SCI ( Deng et al, 2020 ).…”

Section: Empirical Sci Treatment Involving Biomaterial-based Tlr4-nf-...mentioning

confidence: 99%

Strategies for Biomaterial-Based Spinal Cord Injury Repair via the TLR4-NF-κB Signaling Pathway

Shen

Cheng

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The repair and motor functional recovery after spinal cord injury (SCI) has remained a clinical challenge. Injury-induced gliosis and inflammation lead to a physical barrier and an extremely inhibitory microenvironment, which in turn hinders the recovery of SCI. TLR4-NF-κB is a classic implant-related innate immunomodulation signaling pathway and part of numerous biomaterial-based treatment strategies for SCI. Numerous experimental studies have demonstrated that the regulation of TLR4-NF-κB signaling pathway plays an important role in the alleviation of inflammatory responses, the modulation of autophagy, apoptosis and ferroptosis, and the enhancement of anti-oxidative effect post-SCI. An increasing number of novel biomaterials have been fabricated as scaffolds and carriers, loaded with phytochemicals and drugs, to inhibit the progression of SCI through regulation of TLR4-NF-κB. This review summarizes the empirical strategies for the recovery after SCI through individual or composite biomaterials that mediate the TLR4-NF-κB signaling pathway.

show abstract

Long-term clinical observation of patients with acute and chronic complete spinal cord injury after transplantation of NeuroRegen scaffold

Cited by 38 publications

References 48 publications

Current Concepts of Neural Stem/Progenitor Cell Therapy for Chronic Spinal Cord Injury

Current Concepts of Neural Stem/Progenitor Cell Therapy for Chronic Spinal Cord Injury

Comparing the Efficacy and Safety of Cell Transplantation for Spinal Cord Injury: A Systematic Review and Bayesian Network Meta-Analysis

Strategies for Biomaterial-Based Spinal Cord Injury Repair via the TLR4-NF-κB Signaling Pathway

Contact Info

Product

Resources

About